Current treatment for haemophilia is protein substitution therapy Moreover, there is a need to identify the key factors that contribute to the interpatient variability in therapeutic efficacy and safety after gene therapy.
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preclinical animal studies and describe some of the earlier clinical trials. In this review, we will highlight the most recent advances in gene therapy for haemophilia and address some of the outstanding questions. We will highlight some of the key concepts and their clinical translation.
| G ENE THER APY
The ultimate aim of gene therapy for haemophilia is to achieve sustained high-level coagulation factor expression and a stable correction of the bleeding phenotype. Finding a cure for haemophilia requires the delivery of the constructs to the appropriate target cells and the optimization of the coagulation FVIII or FIX expression cassette. The therapeutic gene can be stably integrated into the target cell chromosomes or stay in the nucleus as episomal DNA, depending on the gene delivery vector used. One approach to achieve this is to deliver the FVIII or FIX gene directly in vivo to nondividing postmitotic cells, like hepatocytes or skeletal muscle cells. An alternative approach is to deliver the clotting factor genes into stem/progenitor cells, like haematopoietic stem cells (HSCs). To achieve persisting expression in the HSC progeny, integrating vectors should be used.
Additionally, the induction of inhibitors by gene therapy should be avoided, or the therapy should induce FVIII or FIX-specific immune tolerance, which already has been accomplished in preclinical studies. [11] [12] [13] [14] [15] The induction of immune tolerance to the coagulation factors after gene therapy is dependent on several variables. These include the vector design, target cells, transgene product or the mutation causing the haemophilia disease phenotype.
| Designing optimal FVIII and FIX expression cassettes
All gene therapy approaches focus on expressing the therapeutic protein at high levels while using a low dose of vector to reduce unwanted immune responses or toxicity related to the vector. Mainly for FVIII this has been challenging, because of bottlenecks in expression at the transcriptional, translational and post-translational level. 16 Rationally designed transgenes and expression cassettes are needed to overcome these challenges. If improvements can be made at each of these levels, this could eventually lead to substantial dose benefits for haemophilia patients in clinical trials. Instead of using the full-length transgenes of FVIII and FIX, cDNAs of these genes are used in gene therapy. To improve expression levels, sometimes introns are integrated in the constructs, 17, 18 which are likely to facilitate extra-nuclear transport of the transcripts and subsequent expression.
For haemophilia gene therapy, the use of the endogenous FVIII and FIX promoters would seem attractive to mimic natural expression as much as possible. However, these may not be very robust and hence not very suitable to maximize expression levels in the face of limiting gene transfer efficiencies. Instead, tissue-specific heterologous promoters, like transthyretin or α1-antitrypsin, can be used to boost mRNA levels of FVIII and FIX. [18] [19] [20] Expression can be further increased by combining these promoters with other regulatory elements (e.g. hepatic control regions (HCR), enhancers).
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Although regulatory elements are typically identified through trialand-error, we have developed and experimentally validated an alternative approach to identify robust human tissue-specific cisregulatory modules (CRMs) by means of genomewide data mining.
FVIII or FIX expression could be robustly increased in different gene therapy vectors when these CRMs were combined with existing promoters. [21] [22] [23] While augmenting transgene expression, the risk of insertional oncogenesis of integrating vectors was not increased when using these CRMs, not even in tumour-prone mouse models. 23 Synthetic transcriptional enhancers can also be created de novo by randomly ligating synthetic oligonucleotides coding for hepatic transcription factor binding sites and screening these in vitro in hepatic cell lines. 24 Preclinical mouse models indicate that the cellular specificity of the promoter and regulatory elements is important, because they can have consequences on the immune response directed against the clotting factors (as discussed below). 24, 25 To our knowledge, we were the first to explore the use codonoptimized coagulation factor genes more than 20 years ago 17 in an attempt to augment their expression. The development of codonoptimized FVIII and FIX transgenes led to an increase in protein expression without changing any amino acid sequence of the FVIII or FIX protein. 18, 21, 26, 27 It is therefore encouraging that all of the recent successful gene therapy trials for haemophilia A or B relied on codon optimization to boost expression levels. Preclinical studies revealed that the outcome of the different codon optimization strategies may vary, depending on the transgene and or the algorithm used. For example, typically codon optimization resulted in a twofold to threefold increase in FIX protein expression levels, whereas an increase in FVIII protein expression levels up to 44-fold has been reported. 26 One of the potential advantages of codon optimization is that the amino acids remain unchanged (i.e. synonymous mutations) which may obviate immune concerns, as opposed to nonsynonymous mutations. However, this assumption has recently been challenged as synonymous mutations may inadvertently result in conformational changes in the FIX protein. 28 FVIII expression levels can be enhanced by deleting the Bdomain (FVIIIΔB), because it increased FVIII mRNA levels compared to when the full-length FVIII cDNA was used. 29 However, when the B-domain is deleted, post-translation intracellular FVIII trafficking is compromised because of the loss of critical glycosylated residues. 30 This defect can be counteracted by reintroducing a 17-amino acid synthetic B-domain-derived polypeptide into the FVIIIΔB cDNA, presumably reconstituting these asparagine-linked oligosaccharides, increasing secreted FVIII protein levels around 3-fold. 27 Another possibility is to incorporate a furin cleavage site within the B-domain at position R1645H that is similar to the canine sequence (HHQR vs. RHQR), which increases FVIII expression in haemophilia A mice around twofold. 31 Porcinehuman hybrid FVIIIΔB transgenes could also increase FVIII protein levels. 32 However, overexpression of FVIII above 200% could potentially lead to cellular stress, which possibly increases the risk of inhibitor development. 33 However, we showed that FVIII levels that are up to 75-fold increased compared to physiological levels following liver-directed gene therapy did not result in liver toxicity or transaminitis. 34 The efficacy of gene therapy vectors could also be improved using hyperfunctional clotting factor genes. We have shown that incorporation of a single R338L gain-of-function point mutation in the FIX gene leads to an increase in FIX activity up to eightfold using liver-directed gene therapy. 21, 35 This specific mutation (also known as FIX-Padua) was first discovered in patients suffering from thrombophilia. 36 In a phase I clinical trial for haemophilia A, autologous fibroblasts were electroporated with FVIII-expressing plasmids, after which these were selectively expanded and implanted into the omentum of patients. Despite the fact that there were no adverse effects, the therapeutic efficiency was relatively limited and FVIII expression was not sustained. 
| Adenoviral vectors
The use of adenoviral vectors to treat haemophilia has been explored. However, in the late 1990s, the adenoviral vector trial for ornithine transcarbamylase deficiency failed, and this research has been halted. 57 After systemic administration, there is a risk of uncontrollable inflammatory reactions that can possibly be lethal, which is a main drawback for adenoviral gene therapy.
We and others have shown that supraphysiological coagulation factor levels can be reached after high-capacity adenoviral gene therapy with vectors without any viral genes and encoding for the FVIII or FIX gene, without evident toxicity and inflammation in mouse and dog models of haemophilia. 34, 58, 59 In severe haemophilia A patients, a phase I clinical trial was performed, in which a high-capacity adenoviral vector encoding for the FVIII gene was administered systemically. The first treated patient seemed to express low FVIII levels above the 1% threshold.
However, the trial was discontinued after that patient showed signs of a transient inflammatory response with haematologic and liver abnormalities due to the vector infusion. It is therefore necessary to minimize the interaction between adenoviral vectors and the innate immune system, e.g. by localizing the delivery of the vectors. 60 Based on these concerns and given the success of AAV-based gene therapies, it seems unlikely that adenoviral vectors would become a realistic option for haemophilia any time soon. that contain an inactivation mutation in the integrase. In comparison with conventional integrase-competent lentiviral vectors, there was a reduction in transgene expression levels. 71 However, we showed that when the FIX-R338L Padua variant was incorporated, relatively robust levels of FIX activity could be achieved even when IDLVs 35 were employed. Whether the slow hepatocyte turn-over would eventually contribute to a decline in transgene expression remains uncertain at this point.
| γ-Retroviral and lentiviral vectors

| Adeno-associated viral vectors (AAV)
Haemophilia B
Stable FIX expression could be reached after muscle-directed gene transfer in murine or canine models for haemophilia B that carry a missense mutation. 81, 82 However, when haemophilia B dogs have a FIX null mutation, the induction of high-titre inhibitors after muscledirected gene therapy limits phenotypic correction. 83 The intravas- Because of these successful liver-directed gene therapy studies, a phase I clinical trial was carried out using AAV vectors containing the FIX gene in severe haemophilia B patients. In this trial, promising therapeutic FIX levels of almost 12% were reached. 99 Unfortunately, gene therapy vector containing a codon-optimized FIX gene driven by a liver-specific promoter. 73, 96 AAV8 is able to increase transduction in hepatocytes compared to other serotypes, at least in mice, but this does not automatically mean it can be translated to higher species. 103, 104 One advantage of the AAV8 serotype is that it shows less cross-reactivity with pre-existing antibodies against AAV2. Also, preclinical studies have indicated that the uptake of the capsid by dendritic cells could be decreased compared to AAV2 vectors, which could reduce T-cell activation. 105 Expression levels varied between 1 and 6% of normal FIX levels over a period of around 3 years, which had not been shown previously. All 6 patients in the group receiving the highest dose (2 × 10 12 vg/kg) reached expression levels up to 5% of normal FIX. These patients displayed more than 90% less bleeding episodes and prophylactic treatment with FIX concentrate.
AAV-specific T-cell responses were also observed in this clinical trial, though not in all subjects.
The same vector design was used in a more recent clinical trial (UniQure; NCT02396342), although here AAV5 was used instead of AAV8. Approximately 4% of FIX expression levels was achieved in the patients that received a dose of 5 × 10 12 vg/kg of the AMT-060
vector. 106 When a higher dose was given (2 × 10 13 vg/kg) to another patient cohort, the FIX expression levels improved to almost 7%.
These patients showed a reduction in spontaneous bleeding rates and FIX prophylactic treatment. Eight of 9 patients receiving prophylactic treatment before gene therapy treatment did no longer need prophylaxis. Additionally, no AAV-specific T-cell responses were observed during this trial.
Hence, to achieve comparable FIX levels as what had been reported in the UCL/St Jude's trial, it would appear that a 2.5-to 10-fold higher vector dose was used in the UniQure trial. However, it remains challenging to draw definite conclusions from these trials in the absence of any head-to-head comparison and the low patient numbers. Additionally, there might be other confounding variables that could have an impact on the outcome of the trial, such as variability in viral production methods, the purity of the vectors, patient-specific features. Remarkably, transaminase levels were raised in patients in both the AAV5 and AAV8 trials, which could also be detected in the initial AAV2 trial. 99 Consequently, patients were given a transient immunosuppressive treatment with glucocorticoids to attempt to block unwanted immune responses. Although there is indirect evidence backing up the "T-cell hypothesis" mentioned above, not all patients in the AAV8 trial with an increased AAV capsid-specific T-cell response had elevated liver enzyme levels. Furthermore, other patients in both the AAV5 and AAV8 trial showed the opposite effect: elevated liver enzyme levels without an AAV capsid-specific T-cell response. This implies that the presence of vector-specific T cells in the circulation might not necessarily be related to the immune rejection of hepatocytes transduced with AAV, possibly because the liver microenvironment can have an effect on the local T-cell response. Another possibility is that the elevated liver enzyme levels are not caused by the AAV-specific Tcell response or the response was not strong enough to clear the transduce hepatocytes. These controversies could eventually be elucidated by mouse models that are able to simulate these immune responses or by subsequent clinical trials. 102 The previously discussed AAV2, AAV5 and AAV8 trials indicate that it is still important to further enhance the efficiency of these vectors, so lower, and thus safer, effective vector doses could be administered, which do not result in transaminitis. The use of a hyperfunctional codon-optimized FIX-R338L Padua variant led to a substantial dose advantage with no evidence of an increased risk of thrombosis or immunogenicity in comparison with wild-type FIX after liver-directed gene therapy in mouse models. 21, 35 Other studies have validated these results, also in canine models by Dr. Arruda and colleagues. 14, 37, 39 Therefore, the hyperfunctional FIX-R338L Padua variant is a very interesting treatment option for haemophilia B gene therapy.
In In another more recent study, an AAV8 vector with a 5. 115 Seven of those patients were treated with the highest dose of 6 × 10 13 vg/kg after a dose escalation study.
Six of 7 patients treated with the highest dose of 6 × 10 13 vg/ kg showed a gradual increase in FVIII activity levels and reached more than 50% of normal FVIII activity levels after 20 weeks, when steady-state levels were attained. After 52 weeks, a mean FVIII activity level of 93 ± 48% was achieved for the patients receiving the highest dose. In four of the patients, levels of more than 150% of normal FVIII activity levels were reached, with peaks ranging from 201 to 349% of normal. The six patients of the highest dose that were previously on FVIII prophylaxis showed a reduction in annualized bleeding rate from 16 to 1 event per year after treatment. The median annualized FVIII infusion rate dropped from 138 infusions per year to 2 after gene transfer and was actually 0 since week 2.
However, the patients in the high-dose cohort showed increased transaminase levels, but these were asymptomatic. These patients did require glucocorticoid treatment after the gene therapy treatment, which was tapered off successfully for all patients. During the 1-year follow-up, there was no indication of the presence of FVIII inhibitors or T-cell-mediated immune responses to the AAV5 capsid. In this trial, the vector doses were substantially higher than previously used in AAV-based haemophilia trials, which causes challenges during vector manufacturing.
| CON CLUS I ON S AND PER S PEC TIVE S
The recent results of haemophilia clinical trials yielded the most encouraging results to date, showing sustained FIX and FVIII expression levels and a reduced bleeding rate and recombinant coagulation factor use, without requiring further prophylaxis.
In particular, the improvements of vector designs or using im- Nevertheless, efficient site-specific integrating vectors based on designer zinc finger nucleases, CRISPR/Cas9 or nuclease-free targeting approaches into "safe harbour" loci could potentially minimize this risk. [124] [125] [126] [127] These nucleases induce a double-strand break at the desired locus, increasing the efficiency of directed homologous recombination at least 10 000 to 100 000-fold. These gene-editing approaches had led to sustained clotting factor levels in haemophilic mice by either correcting the mutated clotting fac- Ultimately, it will be necessary to develop gene therapy strategies that could also be employed in patients with pre-existing immunity to the vectors or even with high-titre inhibitors or a higher risk of inhibitor development than in the initial patient cohorts in these early phase I/II trials. Eventually pivotal trials are needed for marketing authorization approval by the regulatory authorities.
Only then will gene therapy make a real difference for patients suffering from haemophilia and their families.
ACK N OWLED G EM ENTS
We thank the members of the Department of Gene Therapy & Regenerative Medicine and all our collaborators for their various contributions to some of the work presented in this review. We also wish to thank FWO, Shire, Bayer, Pfizer, VUB-IOF-GEAR (GENEFIX), Strategic Research Project Grower, AFM, Willy Gepts Fund for providing financial support.
D I SCLOS U R E S
The authors have patent applications and granted patents in the field of gene therapy for haemophilia. They also received industrial grants and/or consultancies from various companies involved in gene therapy for haemophilia (Shire, Bayer, Pfizer).
